Evidence map›Paper›PMID 42645424›Full record

ReviewAntibodies (Basel, Switzerland)2026

Functional Parameters of Hybridoma Cells: Methods of Evaluation and Biotechnological Relevance.

Tatiana Bezukladnikova, Svetlana Zamorina, Sergey Lazarev, Mikhail Rayev

Abstract readReview
In one paragraph

Review in Antibodies (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tatiana BezukladnikovaPerm Federal Research Center of the Ural Branch of the Russian Academy of Sciences, Institute of Ecology and Genetics of Microorganisms, 614081 Perm, Russia.ORCID 0009-0009-3164-3176
Svetlana ZamorinaPerm Federal Research Center of the Ural Branch of the Russian Academy of Sciences, Institute of Ecology and Genetics of Microorganisms, 614081 Perm, Russia.ORCID 0000-0002-6474-1487
Sergey LazarevPerm Federal Research Center of the Ural Branch of the Russian Academy of Sciences, Institute of Ecology and Genetics of Microorganisms, 614081 Perm, Russia.ORCID 0000-0002-0229-1812
Mikhail RayevPerm Federal Research Center of the Ural Branch of the Russian Academy of Sciences, Institute of Ecology and Genetics of Microorganisms, 614081 Perm, Russia.ORCID 0000-0001-6882-4928

Funding

Ministry of Science and Higher Education 124020500027-7
6 · The paper itself

Abstract

Hybridoma technology remains one of the most reliable and widely used platforms for generating highly specific monoclonal antibodies for use in diagnostics, fundamental research, and clinical practice. Moreover, the combination of unlimited proliferative capacity with the preservation of a key B-lymphocyte function, antibody production, enables hybridoma cells to support a comprehensive functional evaluation of cellular responses. Thus, by integrating analysis of proliferation, viability, and productivity, hybridoma-based approaches enable the detection of differential modulatory effects and offer a nuanced assessment of compound bioactivity. This review provides a comprehensive analysis of the functional parameters of hybridoma cells: viability, proliferation, and productivity, as well as the methods used for their evaluation. The main stages of hybridoma cell generation, advances in hybridoma technology, and current applications of hybridoma cells are also reviewed. A key aspect of this review is the differential modulation of functional parameters of hybridoma cells. Modulation of culture conditions and bioactive compounds can differentially influence growth dynamics and specific antibody yield, often revealing an inverse relationship between proliferation and productivity.

Indexed as

functional parametershybridoma technologymonoclonal antibodyproductivityproliferationviability

Identifiers

PMID42645424
PMCPMC13509340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.